Einrichtungen Einrichtung-Details

Klinik für Urologie und Kinderurologie - Ruppiner Kliniken

Link zur Website der Klinik für Urologie und Kinderurologie

Wissenschaftliche Schwerpunkte

Keine laufenden Projekte

Ausgewählte Publikationen

Wolff I, May M, Hoschke B, Gilfrich C, Peter J, Ecke T, Schostak M, Lebentrau S. [Differences between the inpatient complication rate after ureterorenoscopy and the 30-day outcome reported by the patient - results of the German prospective BUSTER study]. Aktuelle Urol. 2018.
http://www.ncbi.nlm.nih.gov/pubmed/29895078?dopt=Citation

May M, Schostak M, Lebentrau S, MR2- study group. Guidelines for patients with acute uncomplicated cystitis may not be a paper tiger: a call for its implementation in clinical routine. Int Urogynecol J. 2018.
http://www.ncbi.nlm.nih.gov/pubmed/30564871?dopt=Citation

Lebentrau S, Enzmann T, Lehsnau M, Christoph F, Schostak M, May M, BUSTER study group. Hospital volume in ureterorenoscopic stone treatment: 99 operations per year could increase the chance of a better outcome-results of the German prospective multicentre BUSTER project. World J Urol. 2018.
http://www.ncbi.nlm.nih.gov/pubmed/30094717?dopt=Citation

Wolff I, Lebentrau S, Miernik A, Ecke T, Gilfrich C, Hoschke B, Schostak M, May M, BUSTER study group. Impact of surgeon's experience on outcome parameters following ureterorenoscopic stone removal. Urolithiasis. 2018.
http://www.ncbi.nlm.nih.gov/pubmed/29974193?dopt=Citation

May M, Schönthaler M, Gilfrich C, Wolff I, Peter J, Miernik A, Fritsche HM, Burger M, Schostak M, Lebentrau S, BUSTER-Arbeitsgruppe. [Interrater reliability and clinical impact of the Post-Ureteroscopic Lesion Scale (PULS) grading system for ureteral lesions after ureteroscopy: Results of the German prospective multicenter BUSTER project]. Urologe A. 2018;57(2):172-180.
http://www.ncbi.nlm.nih.gov/pubmed/29322235?dopt=Citation

Roiner M, Maurer O, Lebentrau S, Gilfrich C, Schäfer C, Haberl C, Brookman-May SD, Burger M, May M, Hakenberg OW. [Management of penile cancer patients: new aspects of a rare tumour entity]. Aktuelle Urol. 2018;49(3):242-249.
http://www.ncbi.nlm.nih.gov/pubmed/29237189?dopt=Citation

Christoph F, König F, Lebentrau S, Jandrig B, Krause H, Strenziok R, Schostak M. RANKL/RANK/OPG cytokine receptor system: mRNA expression pattern in BPH, primary and metastatic prostate cancer disease. World J Urol. 2018;36(2):187-192.
http://www.ncbi.nlm.nih.gov/pubmed/29204705?dopt=Citation

Lebentrau S, Gilfrich C, Vetterlein MW, Schumacher H, Spachmann PJ, Brookman-May SD, Fritsche HM, Schostak M, Wagenlehner FM, Burger M, May M. Re: Letter to the editor. Int Urol Nephrol. 2018;50(5):875.
http://www.ncbi.nlm.nih.gov/pubmed/29441478?dopt=Citation

Lebentrau S, Müller PF, Miernik A, Schönthaler M, Gilfrich C, Peter J, Schostak M, May M, BUSTER study group. Risk Factors for Ureteral Damage in Ureteroscopic stone Treatment: Results of the German Prospective Multicentre Benchmarks of Ureterorenoscopic Stone Treatment-Results in Terms of Complications, Quality of Life, and Stone-Free Rates Project. Urol Int. 2018;1-7.
http://www.ncbi.nlm.nih.gov/pubmed/30481771?dopt=Citation

Lebentrau S, May M, Ziegler H, Werthemann P, Enzmann T, Schostak M, Porsch M, BUSTER-Studiengruppe. [The recommendations of the S2k guideline for the diagnosis, therapy and metaphylaxis of urolithiasis provide a safe course of action for ureterorenoscopic stone treatment - results of the BUSTER study]. Aktuelle Urol. 2018;49(2):164-170.
http://www.ncbi.nlm.nih.gov/pubmed/29025177?dopt=Citation

Christoph F, König F, Lebentrau S, Blaschke S, Liehr UB, Schostak M. [Thermochemotherapy with Mitomycin C: an update on alternative treatment strategies in non-muscleinvasive bladder cancer]. Aktuelle Urol. 2018;49(2):157-163.
http://www.ncbi.nlm.nih.gov/pubmed/28926864?dopt=Citation

 


Leitung: